fashion -WSS

fashion

author：focus 2025-10-02 13:14:28 - browse：9131

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： The science behind Janet Jackson's pregnancy at 49

knowledge

WSS

CDC director unscathed in first congressional testimony

30 years of 'Listening to Prozac'

New guidelines on severe brain injury complicate already difficult decisions

ReNAgade cuts staff seven months after raising $300 million

Despite FDA concern, risk that CAR

The battle over the Brookhaven Landfill on Long Island

hotspot

fashion

focus

23andMe had bad news about my health. I wish a person had delivered it

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Walensky prepares to leave CDC — and Congress — behind

What don’t we know about an Alzheimer’s drug side effect?

Peter Hotez and the public health issue of online harassment

Cloning humans is technically possible. It's curious no one has tried

ChatGPT in medicine: STAT answers readers' burning questions

Organ aging and disease risk measured by new blood test

Anesthesiologist group: stop taking Ozempic before surgery

What would happen to your eyes if you looked at the solar eclipse?

leisure time

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Pediatric cancer treatments threatened by a new FDA policy

Weight bias in eating disorder treatment complicated by new weight loss drugs

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Rep. Raul Ruiz on the physician shortage and more

Disappointing trial forces Pfizer to pivot on obesity medicine plans

leisure time

focus

knowledge

Wikipedia